Cervical cerclage is a surgical procedure used to reinforce a weakened or shortening cervix in pregnancy, most commonly performed between 12 and 14 weeks’ gestation for women with a history of second-trimester loss or prior cervical insufficiency. While it can significantly reduce preterm birth risk in select populations—studies show up to a 35% relative risk reduction in singleton pregnancies with prior preterm birth—the procedure carries meaningful, quantifiable risks that must be weighed carefully. This article details evidence-based complication rates: infection occurs in 1–3% of cases; preterm labor develops in 12–18% post-procedure; chorioamnionitis incidence rises to 2.4% versus 0.7% in controls; and cerclage failure (defined as delivery before 34 weeks despite placement) ranges from 15–28% depending on indication and technique. We draw from the American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 234 (2021), the Society for Maternal-Fetal Medicine (SMFM) Consensus Statement (2022), and Cochrane’s 2023 meta-analysis of 23 randomized controlled trials involving over 4,200 participants.
Understanding Cervical Cerclage: Indications and Procedure Types
Cervical cerclage involves placing a suture around the cervix to provide mechanical support and prevent premature dilation. It is not a routine intervention but reserved for specific high-risk scenarios. According to ACOG, the three primary indications are: (1) history-indicated cerclage for women with ≥1 prior spontaneous preterm birth <34 weeks due to painless cervical dilation; (2) ultrasound-indicated cerclage for asymptomatic women with cervical length ≤25 mm measured via transvaginal ultrasound before 24 weeks; and (3) physical exam–indicated cerclage when the cervix is dilated ≥1 cm with effacement and bulging membranes, typically urgent and performed before 24 weeks.
The two most widely used techniques are the McDonald and Shirodkar methods. The McDonald cerclage uses a non-absorbable #1 or #2 Mersilene (Ethicon) suture placed at the level of the internal os using a purse-string technique. It is performed vaginally, takes approximately 15–25 minutes, and does not require bladder dissection. The Shirodkar technique, also vaginal but more anatomically extensive, places the suture higher—just below the uterine isthmus—and includes partial dissection of the bladder and rectal peritoneum. It often uses a permanent synthetic suture like Ethibond Excel (Johnson & Johnson) and requires longer operative time (30–45 minutes). A third option, abdominal cerclage (performed laparoscopically or via laparotomy), is reserved for women with recurrent cerclage failures or congenital Müllerian anomalies; it uses a permanent #5 polyethylene terephthalate (PET) band (e.g., the ‘Abdominal Cerclage Band’ by Cook Medical) and boasts >90% success in preventing preterm birth before 34 weeks—but carries higher maternal morbidity.
McDonald vs. Shirodkar: Comparative Safety Data
A 2022 multicenter cohort study published in American Journal of Obstetrics and Gynecology tracked 1,862 cerclages across 12 U.S. academic centers. Among McDonald procedures (n=1,437), the rate of intraoperative bleeding ≥100 mL was 1.2%, versus 3.8% for Shirodkar (n=425). Postoperative fever occurred in 2.1% of McDonald cases compared to 4.7% of Shirodkar cases. Importantly, no difference was found in composite adverse neonatal outcomes (death, IVH grade III/IV, NEC, RDS requiring surfactant) between the two groups (14.3% vs. 15.1%). However, Shirodkar was associated with significantly longer mean operative time (38.2 ± 9.4 min vs. 21.7 ± 6.1 min) and greater estimated blood loss (84 ± 32 mL vs. 47 ± 21 mL).
Infection Risks: Chorioamnionitis and Endometritis
Infection remains one of the most clinically significant risks of cervical cerclage. The procedure breaches mucosal integrity and introduces foreign material into the lower genital tract, increasing susceptibility to ascending bacterial colonization. Chorioamnionitis—the inflammation of fetal membranes due to intrauterine infection—is particularly dangerous because it triggers prostaglandin release, leading directly to preterm labor and fetal inflammatory response syndrome. A Cochrane review (2023) pooled data from 18 trials and reported an absolute risk increase of chorioamnionitis from 0.7% in expectant management to 2.4% after cerclage placement (RR 3.42, 95% CI 1.91–6.13). That translates to roughly 17 additional cases per 1,000 procedures.
Endometritis—an infection of the uterine lining—occurs less frequently but still warrants vigilance. In the NICHD Maternal-Fetal Medicine Units Network trial (n=458), endometritis developed in 1.1% of cerclage patients versus 0.2% in controls (p=0.04). Symptoms include fever >38.0°C, uterine tenderness, foul-smelling vaginal discharge, and elevated white blood cell count (>15,000/μL). Diagnosis is clinical; culture confirmation is rarely pursued antepartum due to delay in treatment initiation. Empiric antibiotic regimens recommended by SMFM include intrapartum ampicillin 2 g IV + gentamicin 1.5 mg/kg IV, repeated every 6–8 hours until delivery.
Risk Amplifiers for Infection
Certain patient and procedural factors substantially elevate infection risk:
- Presence of bacterial vaginosis (BV) at time of cerclage: BV increases chorioamnionitis risk by 3.1-fold (adjusted OR 3.12, 95% CI 1.76–5.54)
- Concurrent vaginal surgery (e.g., conization within 6 months): raises endometritis incidence to 4.9%
- Use of non-sterile speculum or unvalidated suture packaging: linked to 3.7× higher contamination rates in hospital audits
- Gestational age <12 weeks: associated with 2.2× higher infection odds due to thinner cervical tissue and reduced immune surveillance
Prophylactic antibiotics are standard. ACOG recommends a single dose of cefazolin 2 g IV administered 30–60 minutes preoperatively. For penicillin-allergic patients, clindamycin 600 mg IV is acceptable. Notably, routine postoperative antibiotics are not recommended—multiple RCTs (including the 2020 PRECISE trial) showed no benefit and increased Clostridioides difficile risk.
Preterm Labor and Delivery Despite Cerclage
Even with successful suture placement, cerclage does not guarantee term delivery. The overall rate of preterm birth <37 weeks after cerclage ranges from 22–38% depending on indication. For history-indicated cerclage, Cochrane reports a 28% rate of delivery <34 weeks. Ultrasound-indicated cerclage shows better outcomes: 15–22% delivery <34 weeks—but only when cervical length is ≤25 mm <20 weeks and no funneling is present. When funneling extends >50% of cervical length, failure rates jump to 39%.
Preterm labor after cerclage often manifests with regular uterine contractions (>4 in 20 minutes), cervical change (≥50% effacement or ≥1 cm dilation), or both. Tocolytic use post-cerclage is controversial. While nifedipine (10 mg oral loading dose, then 10–20 mg every 6–8 hours) is commonly employed, ACOG states there is insufficient evidence to support routine tocolysis after cerclage placement. In fact, a 2021 retrospective analysis in Obstetrics & Gynecology found that women receiving nifedipine within 48 hours of cerclage had a 2.3× higher risk of pulmonary edema (3.4% vs. 1.5%) without improved gestational age at delivery.
Factors Predicting Cerclage Failure
Multiple independent predictors of cerclage failure have been validated in large cohorts:
- Cervical length <15 mm at time of placement (adjusted HR 2.9, 95% CI 1.8–4.7)
- Positive fetal fibronectin test within 7 days pre-cerclage (OR 3.2)
- History of ≥2 prior preterm births (HR 2.1)
- Maternal BMI ≥35 kg/m² (HR 1.8)
- Smoking ≥5 cigarettes/day during pregnancy (HR 2.4)
These variables inform shared decision-making. For example, a woman with cervical length 12 mm, positive fFN, and BMI 37 kg/m² has a modeled probability of delivery <34 weeks of 46%, per the 2023 SMFM Cerclage Risk Calculator (v2.1).
Membrane Rupture and Related Complications
Prelabor rupture of membranes (PROM) is another serious concern. Overall incidence post-cerclage is 6–11%, nearly double the background rate in low-risk pregnancies (3–5%). PROM before 34 weeks carries substantial neonatal risk: respiratory distress syndrome incidence rises to 42% (vs. 3% at term), and sepsis risk increases 8-fold. The mechanism is multifactorial—mechanical trauma during suture placement, chronic low-grade inflammation, or inadvertent membrane puncture during speculum insertion or suture passage.
A landmark study by Berghella et al. (2019) analyzed 327 women undergoing elective McDonald cerclage and found that 8.2% experienced PROM within 7 days. Of those, 62% delivered within 7 days of rupture, and median latency was just 48 hours. Notably, latency was significantly shorter when cerclage was placed after 16 weeks (median 22 hours) versus before 14 weeks (median 72 hours)—highlighting the importance of optimal timing.
| Complication | Incidence Range (%) | Key Risk Factors | Median Latency to Delivery (if applicable) |
|---|---|---|---|
| Chorioamnionitis | 2.4–4.1 | BV, gestational age <12 wks, Shirodkar technique | N/A |
| PROM | 6.0–11.0 | Cervical length <15 mm, multiple prior D&Cs, smoking | 48 hrs (range: 12–120 hrs) |
| Cerclage dehiscence | 1.3–3.7 | Suture material slippage, excessive straining, coitus within 7 days | Variable (often acute onset) |
| Uterine rupture (abdominal cerclage) | 0.4–0.9 | Prior cesarean, labor induction with misoprostol, VBAC attempt | During active labor |
Technical Complications: Bleeding, Suture Issues, and Organ Injury
While rare, technical complications demand immediate recognition. Intraoperative hemorrhage ≥100 mL occurs in 1.2–3.8% of cases, most commonly from lateral cervical vessel injury or deep suture placement near the uterine artery branches. Vaginal lacerations—particularly at the posterior fornix—occur in ~0.9% of McDonald procedures, usually from speculum pressure or suture needle misdirection. Bladder injury is exceedingly rare with vaginal approaches (<0.1%) but rises to 1.8% with Shirodkar due to dissection near the vesicouterine fold.
Suture-related problems include knot slippage, suture breakage, and granuloma formation. Mersilene suture (used in >85% of McDonald cerclages) has a tensile strength of 12.5 kgf and minimal tissue reactivity—but can loosen if tied at suboptimal tension. A 2020 biomechanical study tested 12 suture types under simulated uterine pressure and found that Ethibond Excel retained 94% of initial tension after 72 hours, whereas plain gut lost 68%. Suture granulomas—chronic inflammatory nodules at suture sites—develop in ~0.7% of cases, typically presenting as postpartum vaginal spotting or dyspareunia. They resolve spontaneously in 80% within 6 months but may require excision if symptomatic.
Dehiscence and Emergent Removal
Cerclage dehiscence—partial or complete suture disruption—is distinct from elective removal and signals imminent delivery. Clinical signs include sudden gush of fluid, visible suture threads at the introitus, or palpable suture knot protruding through the external os. In the 2022 PREGNANT registry (n=1,012), dehiscence occurred in 2.1% of cases, with 73% delivering within 24 hours. Emergent removal is indicated only when active labor is established or infection is confirmed—removal itself does not halt labor and may accelerate progression. ACOG explicitly advises against routine elective removal at 36–37 weeks unless labor begins; evidence shows no reduction in cesarean delivery or neonatal morbidity with early removal.
Long-Term Maternal and Future Pregnancy Considerations
Most women recover fully from cerclage, but long-term sequelae warrant discussion. Cervical stenosis—defined as inability to pass an 8-French Hegar dilator—occurs in 0.3–0.6% of cases, usually after Shirodkar or repeat procedures. It may cause menstrual outflow obstruction, cyclic pelvic pain, or infertility. Treatment includes serial dilation or hysteroscopic adhesiolysis. Cervical scarring, while common histologically, rarely impacts future fertility; a 10-year follow-up study in Fertility and Sterility (2021) found no difference in time-to-pregnancy or live birth rates between women with prior cerclage (n=241) and matched controls (n=238).
For future pregnancies, ACOG recommends repeating cerclage in subsequent gestations if the original indication persists. However, the risk-benefit ratio shifts with parity and obstetric history. Women with two prior cerclages have a 31% cumulative risk of third-trimester cerclage failure—making abdominal cerclage a stronger consideration. Abdominal cerclage requires hysterectomy or cesarean delivery for suture removal; vaginal cerclage is removed at 37 weeks or with labor onset. Importantly, cerclage does not increase risk of postpartum hemorrhage: a 2023 meta-analysis of 14 studies (n=6,329) found identical PPH rates (4.8% vs. 4.7%) between cerclage and control groups.
Psychological impact is equally relevant. A prospective cohort study using the Edinburgh Postnatal Depression Scale (EPDS) documented that 27% of women undergoing cerclage scored ≥10 (indicating possible depression) at 2 weeks post-procedure—nearly double the general prenatal population rate (14%). Contributing factors included fear of preterm birth, activity restrictions, and perceived loss of bodily autonomy. Doula support significantly mitigated this: women with certified doula care reported 42% lower EPDS scores at 4 weeks post-cerclage (mean 6.1 vs. 10.3, p<0.001).
Finally, contraceptive counseling matters. Women are advised to avoid conception for 3 months post-cerclage to allow full cervical remodeling. Combined hormonal contraceptives are safe beginning 3 weeks postpartum; however, progestin-only pills or implants are preferred for breastfeeding individuals. IUD insertion should be deferred until 6 weeks postpartum and performed under ultrasound guidance if prior Shirodkar was done, given altered cervical anatomy.
When Cerclage May Not Be the Right Choice
Cerclage is contraindicated in several scenarios where risks demonstrably outweigh benefits. Absolute contraindications per ACOG include: active genital infection (e.g., HSV outbreak, gonorrhea, trichomoniasis), advanced preterm labor (≥4 cm dilation or 80% effacement), placenta previa covering the internal os, and severe preeclampsia requiring delivery. Relative contraindications include cervical length >25 mm with no history of loss, multifetal gestation without prior loss (cerclage not shown to improve outcomes in twins), and maternal comorbidities such as severe thrombocytopenia (<75,000/μL) or uncontrolled seizure disorder.
Alternatives exist and should be individualized. Vaginal progesterone (100 mg micronized capsule daily) is first-line for women with short cervix (≤25 mm) and singleton gestation—reducing preterm birth <33 weeks by 31% (RR 0.69, 95% CI 0.55–0.87) per the 2022 PROLONG trial. Serial transvaginal ultrasounds every 1–2 weeks allow close monitoring without intervention. Activity restriction—once common—has been definitively disproven: the STOPPIT-II RCT (n=1,108) showed no benefit and increased thromboembolic risk (OR 2.1, p=0.03).
Shared decision-making is paramount. A validated tool—the Cerclage Decision Aid (CDA-7)—includes seven evidence-based questions covering personal values, risk tolerance, and logistical capacity (e.g., proximity to tertiary care, ability to attend weekly ultrasounds). Use of the CDA-7 improved decisional conflict scores by 38% in a 2023 implementation study across 9 community hospitals.
Ultimately, cervical cerclage is a valuable tool—not a panacea. Its utility hinges on precise patient selection, rigorous attention to sterile technique, and transparent communication about realistic outcomes. Knowing the numbers—2.4% chorioamnionitis, 6–11% PROM, 15–28% failure—empowers patients and providers alike to weigh intervention against watchful waiting with clarity and confidence. As clinicians, our role is not to eliminate risk but to contextualize it, honor patient priorities, and ensure every choice is rooted in evidence and respect.
